Virbac Unveils Canine Cephalexin Tablet

The company reported Tuesday, Virbac Animal Health of Fort Worth, Texas, launched the first chewable cephalexin tablet designed exclusively for dogs.

Virbac Animal Health of Fort Worth, Texas, launched the first chewable cephalexin tablet designed exclusively for dogs, the company reported Tuesday.

The FDA-approved drug, called Rilexine, is indicated for the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.

Previously, veterinarians often relied on the generic human form of cephalexin to treat dogs, but Rilexine is the first drug of its kind approved by the U.S. Food and Drug administration for the veterinary market, Virbac reported. The new drug should overcome some of the drawbacks of prescribing human cephalexin off-label, including a bitter, metallic taste and strong odor, a lack of veterinary-specific guidelines and the inability to tailor doses, Virbac noted.

Pyoderma is one of the most common diseases seen in dogs, and secondary superficial bacterial pyoderma is the most common form of pyoderma, according to Virbac.

Rilexine is available in 150 mg, 300 mg and 600 mg scored doses. The drug should not be prescribed to dogs that have a known allergy to cephalexin or the B-lactam group of antibiotics.

<HOME>

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.